Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia.
Am J Hematol
; 90(2): 97-9, 2015 Feb.
Article
in En
| MEDLINE
| ID: mdl-25345651
ABSTRACT
We compared survival outcomes following myeloablative allotransplant (MAT) or cyclophosphamide/fludarabine (Cy/Flu) nonmyeloablative allotransplant (NMAT) for 165 patients with acute myelogenous leukemia (AML) in remission or without frank relapse. Patients who received NMAT were more likely to be older and have secondary AML and lower performance status. At a median follow-up of 61 months, median event-free survival and overall survival survival were not different between NMAT and MAT in univariate as well as multivariate analyses. Cy/Flu NMAT may provide similar disease control and survival when compared with MAT in patients with AML in remission or without frank relapse.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vidarabine
/
Leukemia, Myeloid, Acute
/
Hematopoietic Stem Cell Transplantation
/
Transplantation Conditioning
/
Cyclophosphamide
/
Neoplasm Recurrence, Local
/
Antineoplastic Agents
Type of study:
Observational_studies
/
Prognostic_studies
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Am J Hematol
Year:
2015
Type:
Article